How to appeal a Humana treatment-resistant depression — rtms, spravato, ect denial

The framework that applies to your appeal

Medicare Advantage plans follow a separate appeal track from commercial plans. Reconsideration must be requested within 60 days; if the plan misses its deadline, the case auto-forwards to the IRE (Maximus).

Humana-specific note: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.

What Humana's policy requires for treatment-resistant depression — rtms, spravato, ect

Cited policy: Humana Commercial Medical Coverage: Brainsway Deep Transcranial Magnetic Stimulation

MDD (H1 coil — FDA Jan 2013) — failure of >=2 adequate antidepressant trials. OCD (H7 coil — FDA Aug 2018) — failure of >=2 SSRIs at max dose >=12 wk + ERP/CBT. Smoking cessation (H4 coil — FDA Aug 2020). Standard 20-session H1 course for MDD with optional taper; OCD course 29 sessions. PHQ-9 / Y-BOCS reauth.

How Humana denies treatment-resistant depression — rtms, spravato, ect — and how to counter it

Where Humana pushes back: 1) NeuroStar required first; 2) OCD requires 4 SSRIs; 3) Deep TMS not equivalent to standard rTMS.

Counter-arguments that hold up: Brainsway Deep TMS H1 coil is independently FDA-cleared (Jan 2013) for MDD — not subordinate to NeuroStar; clinician + patient-specific factors (depth of stimulation, prior NeuroStar failure, anatomic considerations) drive device choice. H7 coil for OCD FDA-cleared Aug 17, 2018 (Carmi AJP 2019 pivotal) — failure of >=2 SSRIs is FDA-label criterion, not 4. APA + International OCD Foundation endorse Deep TMS for treatment-resistant OCD. Deep TMS reaches deeper cortical structures than figure-8 coil, with distinct mechanism of action and FDA-cleared indications.

What Humana typically denies for treatment-resistant depression — rtms, spravato, ect

Across Humana's commercial and Medicare books, denials cluster around a small number of patterns. For treatment-resistant depression — rtms, spravato, ect, expect:

• MA plan step therapy on Part B drugs
• Skilled nursing facility days
• Prior auth on specialty drugs
• OON emergency reduction

Treatments most often denied in this category

These are the treatment-resistant depression — rtms, spravato, ect treatments most often flagged for prior auth, step therapy, or medical necessity review:

• NeuroStar rTMS (10 Hz)
• Brainsway Deep TMS
• Magstim Horizon rTMS
• MagVenture rTMS
• iTBS (theta-burst)
• SAINT / SNT accelerated iTBS

How to submit the appeal to Humana

1. Read the denial letter — note the exact denial reason code and the appeal deadline (60 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Humana cited in the denial.
3. File the appeal through Humana's portal (members: https://www.humana.com ; providers: https://www.humana.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In KY, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Humana's prior-authorization criteria by drug: Humana PA criteria on ApprovalHelp.